Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

PDE4 inhibitors

10 evidence topics · 6 sources

Week 16 clinical response in Trials PSOR-1 and PSOR-2: apremilast label
Endpoint at Week 16, n (%)PSOR-1 placebo (N = 282)PSOR-1 OTEZLA 30 mg BID (N = 562)PSOR-2 placebo (N = 137)PSOR-2 OTEZLA 30 mg BID (N = 274)
PASI-75“15 (5.3)”“186 (33.1)”“8 (5.8)”“79 (28.8)”
sPGA of clear or almost clear“11 (3.9)”“122 (21.7)”“6 (4.4)”“56 (20.4)”
Adverse reactions through week 16 in adults with moderate to severe plaque psoriasis: apremilast label
Adverse reaction, n (%)Placebo (N = 506)OTEZLA 30 mg BID (N = 920)
Diarrhea“32 (6)”“160 (17)”
Nausea“35 (7)”“155 (17)”
Tension headache“21 (4)”“75 (8)”
Headache“19 (4)”“55 (6)”
Network meta-analysis design: bayesian analysis of short-term PASI response at 10 to 16 weeks in 60 trials and a traditional meta-analysis at 44 to 60 weeks

“A bayesian network meta-analysis was conducted to estimate short-term PASI response rates; to account for variation across trials, an ordinal model that adjusted for reference arm response was implemented.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The long-term PASI rates were estimated via a traditional meta-analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In a network meta-analysis of 60 clinical trials for short-term efficacy, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 60 trials meeting all inclusion criteria were included in the base-case NMA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The base-case analysis included all biologics, apremilast, and dimethyl fumarate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The estimated PASI response rates were summarized using posterior medians and their associated 95% credible intervals (CrIs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote